Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05671835 · ClinicalTrials.gov registry record · Phase 2
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Tvardi Therapeutics, Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05671835 is a Phase 2 study that has completed, run by Tvardi Therapeutics, Incorporated. The registered enrollment target is 100 participants.
The verdict
NCT05671835, a Phase 2 study, has completed, sponsored by Tvardi Therapeutics, Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG TTI-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2025-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05671835
The ClinicalTrials.gov registry entry for NCT05671835 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tvardi Therapeutics, Incorporated, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05671835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05671835 about?
NCT05671835 is a clinical study titled "Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis". The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05671835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-15. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT05671835?
The interventions under investigation include: Placebo (DRUG), TTI-101 (DRUG).
Who is sponsoring clinical trial NCT05671835?
This trial is sponsored by Tvardi Therapeutics, Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.